Heron Therapeutics, Inc.
Financials
Valuation Metrics
Heron Therapeutics, Inc.'s Market Cap is $53M. At end of 2025 it was $217M. Ranked #3079 of 3,116 in US market (top 99%), #1440 of 1,472 on NASDAQ (top 98%), #263 of 265 in Pharmaceuticals, Biotechnology & Life Sciences (top 99%) by Market Cap.
Investment Metrics(as of 2026-10-30)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $53M | US#3,079/3,116 Sec#263/265 |
| Revenue | $151M | US#2,603/3,116 Sec#116/265 |
| Net Income | $-34M | US—/3,116 Sec—/265 |
| Total Assets | $252M | US#2,939/3,116 Sec#226/265 |
| Net Assets | $7M | US#2,900/3,116 Sec#238/265 |
| Employees | 128 | US#2,568/3,116 Sec#159/265 |
| Value | ||
| P/B | 7.61x | US#2,517/3,116 Sec#182/265 |
| P/S | 0.35x | US#219/3,116 Sec#3/265 |
| FCF Yield | -23.09% | US—/3,116 Sec—/265 |
| Profitability | ||
| ROA | -13.50% | US#2,711/3,116 Sec#114/265 |
| Op. Margin | -7.19% | US#2,488/3,116 Sec#90/265 |
| Revenue Growth | 0.99% | US#2,123/3,116 Sec#127/265 |
| Financial Health | ||
| Debt Ratio | 3551.74% | US#2,883/3,116 Sec#237/265 |
| Total Debt | $148M | US#2,321/3,116 Sec#103/265 |
| FCF | $-12M | US#2,379/3,116 Sec#89/265 |
| Cash | $21M | US#2,846/3,116 Sec#254/265 |
| Current Ratio | 2.49x | US#959/3,116 Sec#200/265 |
| Performance | ||
| 1Y Return | -75.64% | US#3,058/3,116 Sec#256/265 |
| 1M Return | -11.42% | US#2,207/3,116 Sec#157/265 |
| From 52W High | -82.42% | US#3,064/3,116 Sec#253/265 |
| 1Y MDD | -81.88% | US#3,055/3,116 Sec#249/265 |
| Trading | ||
| Volume | 1,420,930 shares | US#1,624/3,116 Sec#166/265 |
| Trading Value | $404723.00 | US#3,091/3,116 Sec#263/265 |
| Per Share | ||
| EPS | $-0.18 | US—/3,116 Sec—/265 |
| BPS | $0.04 | US#2,797/3,116 Sec#234/265 |
Company Info
Heron Therapeutics, Inc. is a biotechnology firm dedicated to creating innovative therapies for critical patient requirements. The company leverages its proprietary Biochronomer drug delivery platform, an advanced system that enables the controlled release of various short-acting pharmacological agents. This technology ensures therapeutic concentrations are maintained for periods ranging from days to weeks following just a single administration. Among its commercialized products is SUSTOL (granisetron), an extended-release injectable designed to prevent both immediate and delayed nausea and vomiting triggered by moderately emetogenic chemotherapy, or specific anthracycline and cyclophosphamide combination therapies. Additionally, Heron markets CINVANTI, an intravenous formulation of aprepitant. CINVANTI, which acts as a substance P/neurokinin-1 receptor antagonist, is indicated for the prevention of acute and delayed chemotherapy-induced nausea and vomiting in patients undergoing highly or moderately emetogenic cancer chemotherapy. The company's development pipeline includes ZYNRELEF, an innovative dual-acting local anesthetic that combines bupivacaine, a local anesthetic, with a low dose of the nonsteroidal anti-inflammatory drug (NSAID) meloxicam in a single fixed-dose formulation. Also in development is HTX-019, an experimental therapy aimed at preventing postoperative nausea and vomiting (PONV). Furthermore, HTX-034 is being advanced for postoperative pain management and is currently undergoing Phase Ib/II clinical trials, notably in patients recovering from bunionectomy procedures. Originally established in 1983 as A.P. Pharma, Inc., the company adopted its current name, Heron Therapeutics, Inc., in January 2014. Its corporate headquarters are situated in San Diego, California.